Akeso Inc. (stock code: 9926. HK) is a leading biopharmaceutical company established in 2012 with a focus on researching, developing, producing, and commercializing innovative and affordable antibody-based drugs for patients worldwide.

On April 24, 2020, we were officially listed on the Main Board of the Stock Exchange of Hong Kong. Since our inception, we have built a unique integrated R&D innovation system with the ACE Platform and Tetrabody technology at its core, an international standard GMP production system, and an advanced commercialization system. Currently, our company has over 30 innovative drug candidates for major diseases such as cancer, autoimmune, inflammation, and metabolic disorders.

Among them, 19 new drugs are in clinical research, 13 are in pivotal/Phase III clinical trials, and three new drugs have achieved commercial sales (including one external licensing). In August 2021, our PD-1 monoclonal antibody, Anetoco® (Panhema® injection), was approved for market launch. In June 2022, our globally pioneering tumor dual immune checkpoint dual antibody, Katinib® (PD-1/CTLA-4 dual antibody, Kadenili® injection), was approved for market launch.

In December 2022, our another independently developed globally pioneering dual antibody, Erwosyi (PD-1/VEGF dual antibody, AK112), was licensed exclusively to Summit Therapeutics for development and commercialization in the United States, Canada, Europe, and Japan, with an upfront payment of USD 500 million, a total transaction value of up to USD 5 billion, and a low double-digit royalty rate on sales net amount. Akeso Inc